Filtered By:
Source: American Heart Journal
Condition: Bleeding

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 167 results found since Jan 2013.

Racial/Ethnic Differences in Atrial Fibrillation Symptoms, Treatment Patterns, and Outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation (ORBIT-AF) Registry
Conclusion Relative to white and Hispanic patients, black patients with AF had more symptoms, were less likely to receive rhythm control interventions and had lower quality of warfarin management. Despite these differences, clinical events at two years were similar by race and ethnicity.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research

Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial
Conclusions In patients who underwent coronary stent implantation, the addition of cilostazol to aspirin therapy was associated with lower rates of cardiovascular and cerebrovascular events at 2 years compared with aspirin monotherapy.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research

Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial
Conclusion In the FDA-approved cohort of the ENGAGE AF–-TIMI 48 trial, treatment with edoxaban 60/30 mg was superior to warfarin in the prevention of SSE and significantly reduced cardiovascular death and bleeding, especially fatal bleeding and hemorrhagic stroke.
Source: American Heart Journal - December 22, 2015 Category: Cardiology Source Type: research

Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation
Publication date: Available online 1 December 2015 Source:American Heart Journal Author(s): Vincent Johan Nijenhuis, Naoual Bennaghmouch, Mariella Hassell, Jan Baan, Jan Peter van Kuijk, Pierfrancesco Agostoni, Arnoud van ‘t Hof, Peter C. Kievit, Leo Veenstra, Pim van der Harst, Ad F.M. van den Heuvel, Peter den Heijer, Johannes C. Kelder, Vera H. Deneer, Frank van der Kley, Francesco Onorati, Jean Philippe Collet, Francesco Maisano, Azeem Latib, Kurt Huber, Pieter R. Stella, Jurrien M. ten Berg Background Despite improving experience and techniques, ischemic and bleeding complications after Trans...
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research

Edoxaban versus Warfarin in Patients with Non-valvular Atrial Fibrillation in the US FDA Approval Population: An analysis from the ENGAGE AF-TIMI 48 trial
Conclusion In the FDA approved cohort of the ENGAGE AF-TIMI 48 trial, treatment with edoxaban 60/30 mg was superior to warfarin in the prevention of SSE and significantly reduced cardiovascular death and bleeding, especially fatal bleeding and hemorrhagic stroke.
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research

Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock -Design and rationale of CULPRIT-SHOCK trial
Conclusions The CULPRIT-SHOCK trial will address the question of optimal revascularization strategy in patients with multivessel disease and acute myocardial infarction complicated by cardiogenic shock.
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research

Individualised approaches to thrombo-prophylaxis in atrial fibrillation
Publication date: Available online 11 November 2015 Source:American Heart Journal Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in adults over 55 years of age is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart-rate control, and heart-rhythm control comprise the three main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antag...
Source: American Heart Journal - November 12, 2015 Category: Cardiology Source Type: research

Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial
Conclusions Despite its higher acquisition cost, edoxaban is an economically attractive alternative to warfarin for the prevention of stroke and SE in patients with atrial fibrillation and creatinine clearance ≤95mL/min. These results were robust to variation of key model parameters, including assumptions regarding the cost and quality-of-life impact of stroke and bleeding events, and were favorable across both CHADS2 score stroke-risk categories.
Source: American Heart Journal - November 3, 2015 Category: Cardiology Source Type: research

Interleukin-6 and C-reactive protein and Risk for Death and Cardiovascular Events in Patients with Atrial Fibrillation
Conclusion In patients with AF, IL-6 is related to higher risk of stroke and major bleeding, and both markers are related to higher risk of vascular death and the composite of thromboembolic events independent of clinical risk factors. Adjustment for cardiovascular biomarkers attenuated the prognostic value, although IL-6 remained related to mortality, the composite of thromboembolic events, and major bleeding, and CRP to myocardial infarction.
Source: American Heart Journal - October 4, 2015 Category: Cardiology Source Type: research

Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial
Conclusions . Despite its higher acquisition cost, edoxaban is an economically attractive alternative to warfarin for the prevention of stroke and SE in patients with atrial fibrillation and creatinine clearance≤95mL/min. These results were robust to variation of key model parameters, including assumptions regarding the cost and quality-of-life impact of stroke and bleeding events, and were favorable across both CHADS2 score stroke-risk categories.
Source: American Heart Journal - September 26, 2015 Category: Cardiology Source Type: research

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research

Long-term outcomes for women versus men with unstable angina/non–ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial
Conclusions Long-term ischemic and bleeding outcomes in medically managed ACS patients were similar for women versus men, as was treatment-related platelet reactivity. Women had a higher baseline risk profile and, after adjustment, significantly lower risk of the primary composite end point and all-cause death through 30 months.
Source: American Heart Journal - September 19, 2015 Category: Cardiology Source Type: research

Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis
Conclusion In patients with MHV on anticoagulation, eGFR is an independent predictor of major bleeding and death and not TE.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research

Radial versus Femoral Access for Elderly Patients with Acute Coronary Syndrome undergoing Coronary Angiography and Intervention: Insights from the RIVAL Trial
Conclusions Consistent with the overall RIVAL trial population, elderly patients undergoing cardiac catheterization have lower rates of major bleeding or access site complications and higher rates of access site crossover with radial access compared to femoral access.
Source: American Heart Journal - August 16, 2015 Category: Cardiology Source Type: research

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients aged 70years and older – Rationale and design of the POPular AGE-study
Conclusion The POPular AGE is the first randomized controlled trial that will assess whether the treatment strategy with clopidogrel will result in fewer bleeding events without compromising the net clinical benefit in patients≥70years of age with NSTE-ACS, when compared with a treatment strategy with ticagrelor or prasugrel.
Source: American Heart Journal - August 5, 2015 Category: Cardiology Source Type: research